

=> d his ful

(FILE 'HOME' ENTERED AT 13:13:36 ON 12 FEB 2006)

FILE 'HCAPLUS' ENTERED AT 13:13:41 ON 12 FEB 2006

L1 E BENAVIDES JESUS/AU
82 SEA ABB=ON "BENAVIDES JESUS"/AU
E BOCCIO DANIEL/AU
E DANIEL BOCCIO FAY P/AU
E DANIEL BOCCIO, FAY P/AU
E BOCCIO DANIEL/AU
L2 4 SEA ABB=ON ("BOCCIO D"/AU OR "BOCCIO DANIEL"/AU)
E HENIN YVETTE/AU
L3 32 SEA ABB=ON ("HENIN Y"/AU OR "HENIN YVETTE"/AU)
E PIOT GROSJEAN ODILE/AU
L4 4 SEA ABB=ON "PIOT GROSJEAN ODILE"/AU
L5 2 SEA ABB=ON L1 AND L2 AND L3 AND L4
SELECT RN L5 1-1

FILE 'REGISTRY' ENTERED AT 13:16:24 ON 12 FEB 2006

L6 44 SEA ABB=ON (57308-51-7/BI OR 101626-70-4/BI OR 104632-26-0/BI
OR 106-89-8/BI OR 124-63-0/BI OR 130929-57-6/BI OR 134308-13-7/
BI OR 136236-51-6/BI OR 14611-51-9/BI OR 155210-57-4/BI OR
158681-13-1/BI OR 171752-56-0/BI OR 179386-44-8/BI OR 25614-03-
3/BI OR 261924-66-7/BI OR 358970-91-9/BI OR 358970-92-0/BI OR
358970-97-5/BI OR 358971-48-9/BI OR 372-39-4/BI OR 499771-49-2/
BI OR 499771-50-5/BI OR 499771-51-6/BI OR 499771-52-7/BI OR
499771-53-8/BI OR 499771-54-9/BI OR 499771-55-0/BI OR 499771-56
-1/BI OR 499771-57-2/BI OR 499771-58-3/BI OR 499771-59-4/BI OR
499771-60-7/BI OR 499771-61-8/BI OR 500019-91-0/BI OR 500019-92
-1/BI OR 503-29-7/BI OR 5267-41-4/BI OR 58-96-8/BI OR 59-92-7/B
I OR 7101-51-1/BI OR 80373-22-4/BI OR 81409-90-7/BI OR
91374-21-9/BI OR 99755-59-6/BI)

FILE 'HCAPLUS' ENTERED AT 13:16:33 ON 12 FEB 2006

L7 2 SEA ABB=ON L5 AND L6
L8 ANALYZE L7 1 CT : 8 TERMS

FILE 'REGISTRY' ENTERED AT 13:20:49 ON 12 FEB 2006

L9 1 SEA ABB=ON LEVODOPA/CN
L10 1 SEA ABB=ON 358970-97-5/RN

FILE 'HCAPLUS' ENTERED AT 13:21:12 ON 12 FEB 2006

L11 1 SEA ABB=ON (L9 OR ?LEVODOPA?) AND L10

FILE 'USPATFULL' ENTERED AT 13:21:46 ON 12 FEB 2006

L12 1 SEA ABB=ON (L9 OR ?LEVODOPA?) AND L10

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 10 Feb 2006 (20060210/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2006 HIGHEST RN 874099-70-4
DICTIONARY FILE UPDATES: 10 FEB 2006 HIGHEST RN 874099-70-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Feb 2006 (20060209/PD)
FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)
HIGHEST GRANTED PATENT NUMBER: US6996845
HIGHEST APPLICATION PUBLICATION NUMBER: US2006031974
CA INDEXING IS CURRENT THROUGH 9 Feb 2006 (20060209/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Feb 2006 (20060209/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> d que stat l11

L9 1 SEA FILE=REGISTRY ABB=ON LEVODOPA/CN
 L10 1 SEA FILE=REGISTRY ABB=ON 358970-97-5/RN
 L11 1 SEA FILE=HCAPLUS ABB=ON (L9 OR ?LEVODOPA?) AND L10

=> d ibib abs hitstr l11 1-1

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:197162 HCAPLUS

DOCUMENT NUMBER: 138:198654

TITLE: combination of a CB1 receptor antagonist and a brain
 dopaminergic neurotransmission activator,
 pharmaceutical compositions containing them, and their
 use in the treatment of Parkinson's disease

INVENTOR(S): Benavides, Jesus; Boccio, Daniel; Henin, Yvette; Piot,
 Grosjean Odile

PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.

SOURCE: Fr. Demande, 96 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2829028	A1	20030307	FR 2001-11200	20010829
FR 2829028	B1	20041217		
CA 2458348	AA	20030313	CA 2002-2458348	20020828
WO 2003020314	A1	20030313	WO 2002-FR2946	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1423145	A1	20040602	EP 2002-772514	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505551	T2	20050224	JP 2003-524621	20020828
US 2004209861	A1	20041021	US 2004-786810	20040225
PRIORITY APPLN. INFO.:			FR 2001-11200	A 20010829
			WO 2002-FR2946	W 20020828

OTHER SOURCE(S): MARPAT 138:198654

AB The invention discloses the combination of one or more azetidine derivative
 CB1 antagonists and one or more substances which activate dopaminergic
 neurotransmission in the brain, as well as pharmaceutical compns. containing
 them and their use for the treatment of Parkinson's disease. Methods for
 azetidine derivative preparation are described.


IT 358970-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(dopaminergic neurotransmission activator-CB1 receptor antagonist
 combination, pharmaceutical compns., and use in Parkinson's disease
 treatment)

RN 358970-97-5 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

IT 59-92-7, **Levodopa**, biological studies


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)

RN 59-92-7 HCAPLUS

CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d que stat 112

L9 1 SEA FILE=REGISTRY ABB=ON LEVODOPA/CN
L10 1 SEA FILE=REGISTRY ABB=ON 358970-97-5/RN
L12 1 SEA FILE=USPATFULL ABB=ON (L9 OR ?LEVODOPA?) AND L10

=> d ibib abs hitstr 112 1-1

L12 ANSWER 1 OF 1 USPATFULL on STN

ACCESSION NUMBER: 2004:268318 USPATFULL

TITLE: Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

INVENTOR(S): Benavides, Jesus, Chatenay Malabry, FRANCE

Boccio, Daniel, Fay P. Bippov, FRANCE

Henin, Yvette, Paris, FRANCE

Piot-Grosjean, Odile, Choisy Le Roi, FRANCE

Henin, Paris, FRANCE

PATENT ASSIGNEE(S): Aventis Pharma S.A., Cedex, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209861	A1	20041021
APPLICATION INFO.:	US 2004-786810	A1	20040225 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-FR2946, filed on 28 Aug 2002, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2001-11200	20010829
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2468	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 358970-97-5P

(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)

RN 358970-97-5 USPATFULL

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




IT 59-92-7, Levodopa, biological studies
(dopaminergic neurotransmission activator-CB1 receptor antagonist
combination, pharmaceutical compns., and use in Parkinson's disease
treatment)

RN 59-92-7 USPATFULL

CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d ibib abs hitstr 17 1-2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:197162 HCAPLUS

DOCUMENT NUMBER: 138:198654

TITLE: combination of a CB1 receptor antagonist and a brain dopaminergic neurotransmission activator, pharmaceutical compositions containing them, and their use in the treatment of Parkinson's disease

INVENTOR(S): Benavides, Jesus; Boccio, Daniel; Henin, Yvette; Piot, Grosjean Odile

PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.

SOURCE: Fr. Demande, 96 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2829028	A1	20030307	FR 2001-11200	20010829
FR 2829028	B1	20041217		
CA 2458348	AA	20030313	CA 2002-2458348	20020828
WO 2003020314	A1	20030313	WO 2002-FR2946	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1423145	A1	20040602	EP 2002-772514	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505551	T2	20050224	JP 2003-524621	20020828
US 2004209861	A1	20041021	US 2004-786810	20040225
PRIORITY APPLN. INFO.:			FR 2001-11200	A 20010829
			WO 2002-FR2946	W 20020828

OTHER SOURCE(S): MARPAT 138:198654

AB The invention discloses the combination of one or more azetidine derivative CB1 antagonists and one or more substances which activate dopaminergic neurotransmission in the brain, as well as pharmaceutical compns. containing them and their use for the treatment of Parkinson's disease. Methods for azetidine derivative preparation are described.


IT 80373-22-4, Quinpirole 158681-13-1, SR141716A

RL: PAC (Pharmacological activity); BIOL (Biological study)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)

RN 80373-22-4 HCAPLUS


CN 1H-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158681-13-1 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 358970-91-9P 358970-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)

RN 358970-91-9 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 358970-97-5 HCAPLUS
 CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)




IT 58-96-8, Uridine 59-92-7, Levodopa, biological studies
 503-29-7D, Azetidine, derivs. 7101-51-1, CHF 1301
 14611-51-9, Selegiline 25614-03-3, Bromocriptine
 57308-51-7, Duodopa 81409-90-7, Cabergoline
 91374-21-9, Ropinirole 99755-59-6, Rotigotine
 101626-70-4, Talipexole 104632-26-0, Pramipexole
 130929-57-6, Entacapone 134308-13-7, Tolcapone
 136236-51-6, Rasagiline 155210-57-4, BAM-1110
 171752-56-0, Adrogolide 179386-44-8, PNU-95666
 499771-49-2 499771-50-5 499771-51-6
 499771-52-7 499771-53-8 499771-54-9
 499771-55-0 499771-56-1 499771-57-2
 499771-58-3 499771-59-4 499771-60-7
 500019-91-0, TV 1203 500019-92-1, SL 340026
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (dopaminergic neurotransmission activator-CB1 receptor antagonist
 combination, pharmaceutical compns., and use in Parkinson's disease
 treatment)
 RN 58-96-8 HCAPLUS
 CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 59-92-7 HCAPLUS
 CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 503-29-7 HCAPLUS
 CN Azetidine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 7101-51-1 HCAPLUS
 CN L-Tyrosine, 3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 14611-51-9 HCAPLUS
 CN Benzeneethanamine, N,α-dimethyl-N-2-propynyl-, (αR)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 25614-03-3 HCAPLUS
 CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 57308-51-7 HCAPLUS
 CN L-Tyrosine, 3-hydroxy-, mixt. with (α S)- α -hydrazino-3,4-dihydroxy- α -methylbenzenepropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 28860-95-9
 CMF C10 H14 N2 O4

Absolute stereochemistry.




CM 2

CRN 59-92-7

CMF C9 H11 N O4


Absolute stereochemistry.



RN 81409-90-7 HCAPLUS


CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-
[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 91374-21-9 HCAPLUS


CN 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro- (9CI) (CA INDEX
NAME)



RN 99755-59-6 HCAPLUS


CN 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 101626-70-4 HCAPLUS


CN 4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 104632-26-0 HCAPLUS

CN 2,6-Benzothiazolodiamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 130929-57-6 HCAPLUS


CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 134308-13-7 HCAPLUS


CN Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 136236-51-6 HCAPLUS

CN 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 155210-57-4 HCAPLUS


CN Ergoline, 6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 105579-47-3

CMF C18 H21 N5

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 171752-56-0 HCAPLUS

CN Benzo[f]thieno[2,3-c]quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), (5aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179386-44-8 HCAPLUS


CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179386-43-7

CMF C11 H13 N3 O

Absolute stereochemistry. Rotation (-).




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




RN 499771-49-2 HCAPLUS

CN L-Tyrosine, 3-hydroxy-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9

CMF C22 H21 Cl2 N3 O2 S




CM 2

CRN 59-92-7

CMF C9 H11 N O4

Absolute stereochemistry.




RN 499771-50-5 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-3-pyridinyl-, mixt. with 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9


CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 91374-21-9

CMF C16 H24 N2 O




RN 499771-51-6 HCAPLUS

CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-3-pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9

CMF C22 H21 Cl2 N3 O2 S




CM 2

CRN 25614-03-3


CMF C32 H40 Br N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 499771-52-7 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinyl-, mixt. with (6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9

CMF C22 H21 Cl2 N3 O2 S




CM 2

CRN 104632-26-0

CMF C10 H17 N3 S

Absolute stereochemistry. Rotation (-).



RN 499771-53-8 HCAPLUS


CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-

pyridinyl-, mixt. with (1R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine
(9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9

CMF C22 H21 Cl2 N3 O2 S




CM 2

CRN 136236-51-6

CMF C12 H13 N

Absolute stereochemistry. Rotation (+).




RN 499771-54-9 HCAPLUS

CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-,
(2E)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-3-
pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9

CMF C22 H21 Cl2 N3 O2 S




CM 2

CRN 130929-57-6

CMF C14 H15 N3 O5

Double bond geometry as shown.




RN 499771-55-0 HCAPLUS

CN L-Tyrosine, 3-hydroxy-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5

CMF C23 H20 Cl2 F2 N2 O2 S




CM 2

CRN 59-92-7

CMF C9 H11 N O4

Absolute stereochemistry.




RN 499771-56-1 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)-, mixt. with 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5


CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 91374-21-9

CMF C16 H24 N2 O




RN 499771-57-2 HCAPLUS

CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5

CMF C23 H20 Cl2 F2 N2 O2 S




CM 2

CRN 25614-03-3


CMF C32 H40 Br N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 499771-58-3 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)-, mixt. with (6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5

CMF C23 H20 Cl2 F2 N2 O2 S




CM 2

CRN 104632-26-0

CMF C10 H17 N3 S

Absolute stereochemistry. Rotation (-).




RN 499771-59-4 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-difluorophenyl)-, mixt. with (1R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5

CMF C23 H20 Cl2 F2 N2 O2 S




CM 2

CRN 136236-51-6

CMF C12 H13 N

Absolute stereochemistry. Rotation (+).




RN 499771-60-7 HCAPLUS

CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-,
(2E)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidiny]-N-(3,5-
difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5


CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 130929-57-6
 CMF C14 H15 N3 O5

Double bond geometry as shown.



RN 500019-91-0 HCAPLUS
 CN TV 1203 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 500019-92-1 HCAPLUS
 CN SL 340026 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 106-89-8, reactions 124-63-0, Methylsulfonyl chloride
 372-39-4, 3,5-Difluoroaniline 5267-41-4
 358970-92-0

RL: RCT (Reactant); RACT (Reactant or reagent)
 (dopaminergic neurotransmission activator-CB1 receptor antagonist
 combination, pharmaceutical compns., and use in Parkinson's disease
 treatment)


RN 106-89-8 HCAPLUS
 CN Oxirane, (chloromethyl)- (9CI) (CA INDEX NAME)




RN 124-63-0 HCAPLUS
 CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 372-39-4 HCAPLUS
 CN Benzenamine, 3,5-difluoro- (9CI) (CA INDEX NAME)




RN 5267-41-4 HCAPLUS
 CN Benzenemethanamine, 4-chloro- α -(4-chlorophenyl)-, hydrochloride
 (9CI) (CA INDEX NAME)




● HCl

RN 358970-92-0 HCAPLUS
 CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




IT 261924-66-7P 358971-48-9P 499771-61-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (dopaminergic neurotransmission activator-CB1 receptor antagonist
 combination, pharmaceutical compns., and use in Parkinson's disease
 treatment)
 RN 261924-66-7 HCAPLUS
 CN 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 358971-48-9 HCAPLUS

CN Methanesulfonamide, N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 499771-61-8 HCAPLUS

CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]- (9CI)
(CA INDEX NAME)

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:173468 HCAPLUS

DOCUMENT NUMBER: 138:198652

TITLE: Composition for treating Parkinson's disease
containing a CB1 receptor antagonist and an agent
activating dopaminergic neurotransmission in the brainINVENTOR(S): Benavides, Jesus; Boccio, Daniel;
Henin, Yvette; Piot-Grosjean, Odile

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018060	A1	20030306	WO 2002-FR2945	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2829027	A1	20030307	FR 2001-11201	20010829
CA 2458855	AA	20030306	CA 2002-2458855	20020828
EP 1423146	A1	20040602	EP 2002-774886	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505539	T2	20050224	JP 2003-522575	20020828
US 2005107356	A1	20050519	US 2004-786483	20040225
PRIORITY APPLN. INFO.:			FR 2001-11201	A 20010829
			WO 2002-FR2945	W 20020828

OTHER SOURCE(S): MARPAT 138:198652

AB The invention discloses a combination of one or several azetidine derivative Cb1 antagonists and one or several agents activating dopaminergic neurotransmission in the brain, as well as pharmaceutical compns. containing them and their use for treating Parkinson's disease.

IT 58-96-8, Uridine 59-92-7, Levodopa, biological studies

503-29-7D, Azetidine, derivs. 14611-51-9, Selegiline

25614-03-3, Bromocriptine 57308-51-7, CHF 1512

80373-22-4, Quinpirole 81409-90-7, Cabergoline

91374-21-9, Ropinirole 99755-59-6, Rotigotine

104632-26-0, Pramipexole 130929-57-6, Entacapone

134308-13-7, Tolcapone 136236-51-6, Rasagiline

155210-57-4, BAM-1110 158681-13-1, SR141716A

171752-56-0, Adrogolide 179386-44-8, PNU-95666

500019-91-0, TV 1203 500019-92-1, SL 340026

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(Cb1 receptor antagonist combination with agent activating dopaminergic neurotransmission in brain for treating Parkinson's disease)

RN 58-96-8 HCAPLUS

CN Uridine (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 59-92-7 HCAPLUS

CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503-29-7 HCAPLUS


CN Azetidine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 14611-51-9 HCAPLUS

CN Benzeneethanamine, N,α-dimethyl-N-2-propynyl-, (αR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 25614-03-3 HCAPLUS


CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 57308-51-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, mixt. with (α S)- α -hydrazino-3,4-dihydroxy- α -methylbenzenepropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 28860-95-9
CMF C10 H14 N2 O4

Absolute stereochemistry.




CM 2

CRN 59-92-7

CMF C9 H11 N O4


Absolute stereochemistry.



RN 80373-22-4 HCAPLUS

CN 1H-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-,
(4aR,8aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 81409-90-7 HCAPLUS


CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-
[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 91374-21-9 HCAPLUS


CN 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 99755-59-6 HCAPLUS

CN 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 104632-26-0 HCAPLUS

CN 2,6-Benzothiazolodiamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 130929-57-6 HCAPLUS


CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 134308-13-7 HCAPLUS


CN Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 136236-51-6 HCAPLUS

CN 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 155210-57-4 HCAPLUS


CN Ergoline, 6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (8β)-,
(2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 105579-47-3

CMF C18 H21 N5

Absolute stereochemistry.




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 158681-13-1 HCAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171752-56-0 HCAPLUS

CN Benzo[f]thieno[2,3-c]quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), (5aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 179386-44-8 HCAPLUS
 CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-,
 (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179386-43-7
 CMF C11 H13 N3 O


Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 500019-91-0 HCAPLUS
 CN TV 1203 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 500019-92-1 HCAPLUS
 CN SL 340026 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT